Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability
PLOS Pathogens · 29.08.2024 · 20 (8) · e1012422
DOI: 10.1371/journal.ppat.1012422 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 29.08.2024. Verfasst von Samuel E Blechman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Vancomycin, Anti-Bacterial Agents, Staphylococcal Infections, Vancomycin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Vancomycin has proven remarkably durable to resistance evolution by Staphylococcus aureus despite widespread treatment with vancomycin in the clinic. Only 16 cases of vancomycin-resistant S . aureus (VRSA) have been documented in the United States. It is thought that the failure of VRSA to spread is partly due to the fitness cost imposed by the vanA operon, which is the only known means of high-level resistance. Here, we show that the fitness cost of vanA -mediated resistance can be overcome through laboratory evolution of VRSA in the presence of vancomycin. Adaptation to vancomycin imposed a tradeoff such that fitness in the presence of vancomycin increased, while fitness in its absence decreased in evolved lineages. Comparing the genomes of vancomycin-exposed and vancomycin-unexposed lineages pinpointed the D-alanine:D-alanine ligase gene ( ddl ) as the target of loss-of-function mutations, which were associated with the observed fitness tradeoff. Vancomycin-exposed lineages exhibited vancomycin dependence and abnormal colony morphology in the absence of drug, which were associated with mutations in ddl . However, further evolution of vancomycin-exposed lineages in the absence of vancomycin enabled some evolved lineages to escape this fitness tradeoff. Many vancomycin-exposed lineages maintained resistance in the absence of vancomycin, unlike their ancestral VRSA strains. These results indicate that VRSA might be able to compensate for the fitness deficit associated with vanA -mediated resistance, which may pose a threat to the prolonged durability of vancomycin in the clinic. Our results also suggest vancomycin treatment should be immediately discontinued in patients after VRSA is identified to mitigate potential adaptations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
- Center for Evolutionary Biology and Medicine, Pittsburgh, Pennsylvania, United States of America.
ORCID-Profile: Samuel E Blechman, Erik S Wright
Förderung
- NIAID NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Blechman, S. E., & Wright, E. S. (2024). Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability. PLOS Pathogens, 20(8), e1012422. https://doi.org/10.1371/journal.ppat.1012422
Vancouver
Blechman SE, Wright ES. Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability. PLOS Pathogens. 2024;20(8):e1012422. doi:10.1371/journal.ppat.1012422
BibTeX
@article{Blechman2024,
author = {Blechman, Samuel E and Wright, Erik S},
title = {Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability},
journal = {PLOS Pathogens},
year = {2024},
volume = {20},
number = {8},
pages = {e1012422},
doi = {10.1371/journal.ppat.1012422}
}
EUVIMED